CERA

Science and Research

RHINE: A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema

The main aim of the study is to evaluate the effectiveness, safety, pharmacokinetics, and optimal treatment frequency of Faricimab either at 8-week intervals or personalized treatment intervals. 

Overview

This is a two-year, phase III, randomised, double masked, comparator controlled study of the study drug Faricimab, for patients with diabetic macular oedema.

There are three arms to the study: Faricimab on an 8-weekly interval, Faricimab on a personalized treatment interval, and Aflibercept (Eylea) on an 8-weekly interval.

The main aim of the study is to evaluate the effectiveness, safety, pharmacokinetics, and optimal treatment frequency of Faricimab either at 8-week intervals or personalized treatment intervals.

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.